Mar 8 |
Delcath Systems to Participate in Upcoming Investor Conferences
|
Feb 22 |
Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)
|
Feb 15 |
Retail investors account for 52% of Delcath Systems, Inc.'s (NASDAQ:DCTH) ownership, while institutions account for 40%
|
Jan 31 |
Delcath Systems announces CMS established product-specific J-code for HEPZATO
|
Jan 31 |
Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024
|
Jan 23 |
Delcath Systems to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
|
Jan 19 |
Delcath Systems, Inc. (NASDAQ:DCTH): Are Analysts Optimistic?
|
Jan 16 |
Delcath launches Hepzato Kit in US for uveal melanoma
|
Jan 16 |
Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT™
|
Jan 12 |
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|